Bamlanivimab and etesevimab FDA Approval Status
Bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) are two monoclonal antibodies administered together to block the infectivity of SARS-CoV-2, the virus that causes COVID-19.
- The bamlanivimab and etesevimab combination received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) on February 9, 2021. Bamlanivimab and etesevimab are not FDA approved for any use. It is not known if bamlanivimab and etesevimab are safe and effective for the treatment of COVID-19.
- The bamlanivimab and etesevimab combination is authorized for the treatment of mild to moderate COVID-19 in patients aged 12 and older and weighing at least 40 kg who are at high risk for progressing to severe COVID-19 and/or hospitalization. Bamlanivimab and etesevimab should be administered together via a single intravenous infusion as soon as possible after a positive COVID-19 test and within 10 days of symptom onset.
- Bamlanivimab and etesevimab are not authorized for use in patients who are hospitalized or require oxygen therapy due to COVID-19, or for people currently using chronic oxygen therapy because of an underlying comorbidity who require an increase in baseline oxygen flow rate due to COVID-19.
Development Timeline for bamlanivimab and etesevimab
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.